Results 131 to 140 of about 12,396 (213)

Unraveling α-synuclein and amylin co-aggregation: pathological insights and biomarker development for Parkinson's disease. [PDF]

Theranostics
Zhou Y, Lai M, Shu B, Wang B, Wang D, Liu H, Li B, Guo J, Hu D, Li M, Zhu C, Kang M, Li ZA, Wang R, Zhao Y, Tuan RS, Guo K, Li C, Jiang C.   +18 more
europepmc   +1 more source

Neuroendocrinology meets addiction: Emerging pharmacotherapies on the horizon. [PDF]

J Intern Med
Loften A, Farokhnia M, Vendruscolo LF, Leggio L.   +3 more
europepmc   +1 more source

Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes. [PDF]

Metabol Open
Al-Harbi FA, Alsaif AK, Almutairi AG, Alshehri HJ, Aleidan EA, Alabdulaaly GS, Alanazi ME, Azzam AY.   +7 more
europepmc   +1 more source

Amylin/CGRP

, 2013
openaire   +2 more sources

Pharmacological therapies for type 2 diabetes: future approaches. [PDF]

Diabetologia
Bailey CJ.
europepmc   +1 more source

Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management. [PDF]

Endocrinol Metab (Seoul)
Kwak KH, Jung CH.
europepmc   +1 more source

The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. [PDF]

EBioMedicine
Kuhre RE, Ballarín-González B, Brand CL, Glendorf T, Madsen KG, Hjøllund KR, Hogendorf WFJ, Ipsen DH, Lundh S, Kruse T, Petersen SB, Secher A, Vegge A, Raun K.   +13 more
europepmc   +1 more source

Amylin receptor subunit interactions are modulated by agonists and determine signaling. [PDF]

Sci Signal
Gostynska SE, Karim JA, Ford BE, Gordon PH, Babin KM, Inoue A, Lambert NA, Pioszak AA.   +7 more
europepmc   +1 more source